drugset / Trial / NCT04137380
A Study of Mirikizumab in Healthy Chinese Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug. It will last up to about 4 months for each participant.
Timeline
- Start
- 2019-12-04
- Primary completion
- 2020-12-11
- Completion
- 2020-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Mirikizumab | Monoclonal antibody | 1200 mg | Intravenous |
Indications
No indication recorded.